NCT00825721
Unknown
Phase 2
A Randomized, Placebo-Controlled, Single-Masked, Dose-Ranging Study of C-KAD Ophthalmic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataracts
ConditionsNuclear Cataract
Overview
- Phase
- Phase 2
- Intervention
- C-KAD Ophthalmic Solution
- Conditions
- Nuclear Cataract
- Sponsor
- Chakshu Research, Inc.
- Enrollment
- 81
- Locations
- 1
- Primary Endpoint
- Best-corrected visual acuity by ETDRS
- Last Updated
- 17 years ago
Overview
Brief Summary
This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution in patients with loss of visual function due to age-related nuclear cataract
Investigators
Eligibility Criteria
Inclusion Criteria
- •Presence of nuclear sclerosis cataract
- •BCDVA within the range of 20/40 and 20/80
Exclusion Criteria
- •Any other clinical condition in the eye that may compromise vision
- •Presence or history of glaucoma
- •Presence or history of diabetes
- •Use of eyedrops
- •Use of steroids
Arms & Interventions
1.3% (low dose)
Intervention: C-KAD Ophthalmic Solution
2% (medium dose)
Intervention: C-KAD Ophthalmic Solution
2.6% (high dose)
Intervention: C-KAD Ophthalmic Solution
Placebo
Intervention: LiquiTears
Outcomes
Primary Outcomes
Best-corrected visual acuity by ETDRS
Time Frame: 360 days
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 2
Safety and Efficacy Study of an Ophthalmic Solution in Patients With Age-Related CataractCataractNCT00793091Chakshu Research, Inc.80
Completed
Not Applicable
An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular HypertensionOcular HypertensionNCT00825396Chakshu Research, Inc.12
Completed
Phase 3
Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy VolunteersAllergic ConjunctivitisNCT01159015Bausch & Lomb Incorporated534
Completed
Phase 3
A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract SurgeryCorneal Edema After Cataract SurgeryNCT05528172Kowa Research Institute, Inc.331
Completed
Phase 1
Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular HypertensionGlaucomaOcular HypertensionNCT00515424Novartis90